Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura is now fully enrolled. The results of the trial, whose primary endpoint is the reduction in the number of migraine headache days experienced by the trial’s patients, are expected in the second half of this year.

Migraine with aura, which affects around 15 per cent of migraine sufferers, is a type of migraine in which the headache is accompanied by symptoms such as flashing lights and abnormality of speech.

The Phase II trial is being conducted at the Danish Headache Centre at Copenhagen’s Glostrup University Hospital by the Centre’s Director, Professor Jes Olesen, who is one of the world’s leading authorities on headache. The trial is being jointly funded by Minster and the University of Copenhagen.

This placebo-controlled trial has recruited 39 patients, an increase on the initial estimate of 34.  Under the cross-over design, patients take either tonabersat at 40mg once a day or placebo for a three-month period after which the treatment regime is reversed such that those initially on tonabersat receive placebo and vice versa.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment.

Paul Sharpe, Minster Pharmaceuticals’ Chief Executive, said: “Migraine with aura affects a significant sub-population of migraine sufferers. The symptoms can be very troublesome and are frequently not well controlled with current treatments. We are delighted that this jointly funded trial is now fully enrolled and we look forward to the results of the study in the latter half of this year.

For further information:

Minster Pharmaceuticals plc                     Tel: +44 (0) 1799 506623

Paul Sharpe, Chief Executive Officer

Robert Aubrey, Chief Financial Officer

Buchanan Communications                        Tel: +44 (0) 20 7466 5000

Mark Court

Rebecca Skye Dietrich

Nomura Code Securities Limited:             Tel: +44 (0) 20 7776 1200

Richard Potts

Gerard Harper

Notes for editors:

About Minster Pharmaceuticals plc

Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.

Minster’s near-term focus is on the development and commercialisation of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focussed on the central nervous system.

Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com .